Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Afatinib activity against head-and-neck or esophageal squamous cell carcinoma: Significance of activating oncogenic HER4 mutations in head-and-neck squamous cell carcinoma

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Yosuke Togashi

Citation

Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527

Authors

Y. Togashi1, Y. Nakamura2, S. Tomida2, H. Hayashi2, M.A. de Velasco2, K. Sakai2, Y. Fujita2, S. Hamada3, K. Nishio1

Author affiliations

  • 1 Department Of Genome Biology, Kinki University School of Medicine, 589-8511 - Osakasayama/JP
  • 2 Department Of Genome Biology, Kinki University School of Medicine, Osakasayama/JP
  • 3 Department Of Oral And Maxillofacial Surgery, Kinki University School of Medicine, 589-8511 - Osakasayama/JP
More

Resources

Aim/Background

The prognosis for patients with head-and neck or esophageal squamous cell carcinoma (HNSCC or ESCC) remains poor. Thus, this study was performed to identify additional oncogenes coupled with the inhibitors.

Methods

We evaluated the sensitivity to HER inhibitors (cetuximab, erlotinib, and afatinib) in several HNSCC and ESCC cell lines in vitro. In the hypersensitive cell lines, the mechanisms such as gene mutation and amplification were investigated. Furthermore, the frequencies of the identified mechanisms were analyzed using the databases of HNSCC and ESCC.

Results

Two of 12 HNSCC or ESCC cell lines that were hypersensitive to afatinib were identified, whereas no cell line was sensitive to cetuximab or erlotinib. The sequence analyses for the afatinib targeted genes, HER family, in the two cell lines revealed that one cell line had a HER4 mutation whose function had not been investigated, while another had a previously reported activating EGFR mutation. No amplification of HER family gene was found in the two cell lines. The phosphorylation level of HER4 was elevated in the HER4 mutation-overexpressed HEK293 cell line, and the mutation had a transforming potential in the NIH3T3 cell line, indicating that this HER4 mutation is an activating oncogenic mutation. Afatinib dramatically reduced the phosphorylation of EGFR or HER4 and induced apoptosis in the two cell lines. In vivo, tumor growth was also dramatically decreased by afatinib. In the databases, the frequencies of HER family mutations in HNSCC or ESCC ranged from 0% to 5%. Particularly, HER4 mutations have been found relatively frequently in HNSCC.

Conclusions

Considering the addiction of cancer cells to activating EGFR or HER4 mutations for proliferation, HNSCC or ESCC with such oncogenic mutations might be suitable for targeted therapy with afatinib.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings